Joseph McCoy

Executive Profile

Helping Biotechnology Companies Make Better Commercial Decisions

Developing an innovative therapy is one of the most difficult challenges in healthcare.

Bringing that therapy successfully to patients is often even more difficult.

Over the past three decades, I have learned that commercial success is rarely determined by science alone. Innovative products fail every year despite compelling clinical data, while others exceed expectations because leadership identified and solved the commercial barriers long before launch.

Throughout my career, I have worked at the intersection of commercial strategy, physician adoption, market access, institutional healthcare, leadership development, and organizational performance. My experience spans biotechnology, specialty pharmaceuticals, neuroscience, rare disease, endocrinology, hospital systems, the Veterans Health Administration, and academic Centers of Excellence.

I founded PharmaKonsult because emerging biotechnology companies deserve practical commercial guidance from someone who has built organizations, launched products, developed leaders, solved complex commercialization challenges, and made these decisions firsthand.

My Commercial Philosophy

Throughout my career, I have rarely accepted the assumption that "this is how we've always done it."

My greatest commercial successes have come from identifying opportunities others overlooked, questioning conventional thinking, and developing practical strategies that aligned science, healthcare systems, physician behavior, reimbursement, and commercial execution.

Sometimes the obstacle was leadership.

Sometimes it was organizational culture.

Sometimes it was institutional purchasing.

Sometimes it was payer access.

Sometimes it was physician education.

And increasingly, it has been the failure to integrate Medical Affairs, Health Economics, Market Access, and Commercial Leadership early enough in product development.

Every experience throughout my career has reinforced one fundamental belief:

That philosophy is the foundation of PharmaKonsult.

Leadership Was Learned

One of the most important lessons of my career is also one of the most personal.

I was not born a great leader.

Like many young professionals, I became one through experience, humility, difficult feedback, and continuous improvement.

My leadership journey began as an officer in the United States Navy.

During my first assignment, I focused heavily on accomplishing the mission but had not yet learned how to build trust with the people I was responsible for leading. Senior leadership appreciated my work, but I struggled to connect with my team.

Rather than becoming discouraged, I listened, adjusted, sought mentorship, and fundamentally changed my leadership approach.

By my second command, I had become a much more effective leader. Working with an exceptional team, we implemented operational improvements that saved the Navy millions of dollars while significantly reducing repair timelines.

The lesson was lasting.

That philosophy has guided every leadership position I have held since.

Years later, I experienced a similar transformation at Pfizer.

Early leadership feedback again challenged me to become a better communicator, coach, and mentor. I invested heavily in leadership development, coaching methodologies, and management education.

The results were significant.

I was honored with Pfizer's prestigious Situational Leadership Award—an honor presented annually to only one manager among approximately eighty leaders.

More important than the award itself was what it represented.

Leadership can always improve.

That belief continues to shape how I coach executives, evaluate leaders, and build commercial organizations today.

Learning Where Decisions Are Really Made

One of the most influential leaders in my career was Greg Figgins, a former Army Ranger and exceptional commercial executive at Pfizer.

Greg introduced me to Strategic Account Management.

It fundamentally changed how I viewed healthcare.

Instead of asking how to sell more product, I learned to ask different questions.

• Who actually makes the decision?
• What barriers prevent adoption?
• Who controls purchasing?
• Who influences reimbursement?
• Where does the patient journey break down?

Those lessons became the foundation of my commercial philosophy.

Solving Commercial Problems Others Miss

Throughout my career I have repeatedly found that commercial barriers often exist where organizations are not looking.

Pfizer – Improving Hospital Care

While leading hospital-focused initiatives, I developed a practical IV-to-oral transition strategy for Zithromax that aligned clinical care with hospital operations.

Helping hospitals transition appropriate patients from intravenous to oral therapy supported earlier discharge, improved continuity of care, increased bed availability, and reduced healthcare costs while maintaining physician confidence in patient outcomes.

The initiative demonstrated that commercial strategy can improve both patient care and healthcare system efficiency.

During my career at Pfizer, I also had the opportunity to redesign portions of the company's national commercial training program, helping develop thousands of pharmaceutical representatives. The experience reinforced another important lesson: exceptional commercial organizations are built through investment in people, coaching, leadership development, and continuous learning—not simply product knowledge.

Advanced BioHealing – Understanding Institutional Decision Making

One experience at Advanced BioHealing permanently reinforced an important commercial lesson.

Our product had physician support.

It had formulary approval.

It had a national Veterans Administration contract.

Yet sales remained stagnant.

The problem was not clinical evidence.

The problem was institutional purchasing.

After mapping the purchasing process, I identified the regional VISN leadership responsible for oversight, presented the issue, and successfully removed the purchasing barrier.

Regional sales increased approximately 250 percent.

The experience reinforced a principle that still guides my consulting work today.

Lundbeck – Converting Market Access into Market Share

Positive insurance coverage alone does not improve commercial performance.

Commercial organizations must know how to capitalize on that opportunity.

Working closely with our Market Access organization, I identified significant reimbursement improvements within the Federal Employee Program (FEP) serving the Washington, D.C. market.

Rather than broadly increasing activity, my management team developed targeted commercial strategies focused on physicians and patients who now had substantially improved access.

Sales within those targeted markets tripled, and the region earned All-Star recognition for three consecutive years.

The experience reinforced another important lesson.

SK Life Science – Launching During Uncertainty

Joining SK Life Science provided the opportunity to help launch XCOPRI, one of the most significant new therapies in epilepsy in decades. The launch occurred during the unprecedented challenges of the COVID-19 pandemic, requiring new approaches to physician engagement, virtual communication, and commercial execution.

Leading one of the nation's highest-performing regions reinforced the importance of organizational alignment, adaptability, and disciplined execution under difficult circumstances. Our region achieved the #1 national commercial launch, demonstrating that strong leadership and coordinated execution can overcome extraordinary external challenges.

During this period I also completed the internationally respected Penry Mini-Fellowship in Epilepsy, further strengthening my understanding of academic epilepsy centers, multidisciplinary care, referral pathways, and the broader healthcare ecosystem influencing treatment decisions.

Rare Disease Changed My Commercial Philosophy

Rare disease commercialization fundamentally changed how I think about launching products.

Unlike primary care markets, rare disease is concentrated within a relatively small number of academic Centers of Excellence that influence clinical research, treatment guidelines, physician education, referral patterns, and long-term adoption.

Many biotechnology companies continue to build commercialization plans around their future sales organization.

My experience has consistently shown that approach begins too late.

Successful commercialization begins years before launch.

Clinical Development, Medical Affairs, Commercial Leadership, Market Access, Health Economics, Patient Advocacy, and Executive Leadership must work together from the earliest stages of development.

Throughout my work in neuroscience, rare disease commercialization, and strategic planning—including the development of independent commercial strategy proposals for emerging biotechnology opportunities—I have consistently advocated for this integrated approach.

I also believe that health economic and real-world evidence studies should begin far earlier than most organizations currently pursue.

When developed early, these studies can differentiate a therapy beyond clinical efficacy by demonstrating value to physicians, healthcare systems, institutions, and payers before commercialization begins.

Epilepsy Taught Me Systems Thinking

Commercializing therapies in epilepsy reinforced another important lesson.

Commercial success depends upon understanding an entire healthcare ecosystem.

To better understand the disease, I completed the internationally respected Penry Mini-Fellowship in Epilepsy.

The education expanded my understanding well beyond pharmacology and seizure management.

I gained a deeper appreciation for Comprehensive Epilepsy Centers, multidisciplinary care, referral pathways, neurostimulation programs, surgical evaluation, and the economic realities influencing treatment decisions.

That experience reinforced my belief that successful commercialization requires understanding institutional priorities, physician behavior, patient flow, reimbursement, and healthcare economics—not simply clinical efficacy.

Those lessons continue to influence how I advise biotechnology companies preparing for launch.

Endocrinology Reinforced the Importance of Academic Partnerships

My experience commercializing therapies for complex endocrine disorders reinforced many of the same principles I had learned in neuroscience and rare disease.

For diseases such as Cushing's syndrome and Congenital Adrenal Hyperplasia (CAH), patient care is concentrated within a relatively small number of academic medical centers and multidisciplinary specialty programs. These institutions not only manage the most complex patients, but also influence treatment guidelines, physician education, referral patterns, and future standards of care.

Early in my work within endocrinology, I recognized that successful commercialization would require much more than a capable sales organization.

It required long-term scientific engagement with academic thought leaders, closer collaboration between Medical Affairs and Commercial Leadership, and earlier development of evidence that extended beyond efficacy and safety.

In particular, I became increasingly convinced that health economic studies, patient journey analyses, and research focused on the value of earlier diagnosis should begin far earlier in development than is traditionally considered.

Physicians, healthcare systems, and payers increasingly evaluate therapies based not only on clinical outcomes, but also on healthcare utilization, quality of life, resource allocation, and long-term value.

Organizations that invest in these areas early often create meaningful competitive advantages that extend well beyond product launch.

These experiences further reinforced my belief that commercialization begins years before approval—not months before launch.

Executive Impact

• More than 30 years of commercial leadership across biotechnology and specialty pharmaceuticals
• Ten-time Pinnacle Club leader recognized for sustained commercial excellence
• Led the #1 national commercial launch of XCOPRI during the COVID-19 pandemic
• Increased regional commercial performance by 75% while leading the launch of Recorlev
• Redesigned a national Pfizer commercial training program that influenced the development of thousands of representatives
• Developed hospital implementation strategies supporting improved patient transitions and operational efficiency
• Solved complex institutional purchasing barriers within the Veterans Health Administration, increasing regional sales by approximately 250%
• Leveraged payer access strategies that tripled performance within targeted commercial markets
• Recruited, coached, and developed nearly 200 commercial professionals
• Developed more than 25 future sales leaders promoted into management
• Advised organizations across neuroscience, rare disease, endocrinology, market access, institutional healthcare, and commercial leadership
• Successfully led commercial organizations across neuroscience, rare disease, endocrinology, hospital, institutional, and specialty pharmaceutical markets
• Three-time National #1 Sales Director while leading commercial organizations
• Multiple President's Club and National Leadership recognitions spanning more than three decades
• Advisor to emerging biotechnology companies evaluating commercialization strategy, launch readiness, organizational structure, and market positioning

My Consulting Philosophy

Every biotechnology company is different.

Every therapy faces different scientific, commercial, financial, regulatory, and organizational challenges.

There is no universal commercialization template.

The companies most likely to succeed are those that identify commercial barriers early, align every function around a common strategy, and execute with discipline long before FDA approval.

That is the role of PharmaKonsult.

I help biotechnology leadership teams identify the challenges others overlook, develop practical commercialization strategies grounded in real-world experience, and build organizations capable of delivering long-term commercial success.

Education

• Bachelor of Science, Biology — Stony Brook University

Military & Community Leadership

• Lieutenant, United States Navy
• Commercial Leadership Coach and Mentor
• Yoga Alliance Certified Instructor
• Aquatics Instructor
• Supporter of epilepsy, neuroscience, and rare disease advocacy initiatives